About AM-pharma

AM-Pharma’s purpose is to save and improve the lives of patients confronted with severe medical conditions. Our initial focus is sepsis-associated acute kidney injury, the cause of death for hundreds of thousands of people hospitalized each year. Our proprietary compound, ilofotase alfa, has the potential to become the first treatment for sepsis-associated acute kidney injury and is now in a global pivotal Phase III clinical trial. We are a dedicated team driven to bring treatment options to severely ill patients, their families and acute care professionals.

OUR MISSION

At AM-Pharma, we strive to improve the quality of life for patients with severe medical conditions, initially focusing on saving the lives of patients with sepsis-associated acute kidney injury (SA-AKI).

Our investors

LATEST NEWS

AM-Pharma Appoints Martijn Negen as VP Commercial Strategy

Utrecht, The Netherlands, 15 June 2021 – AM-Pharma B.V., an…

LATEST NEWS

AM-Pharma Appoints Martijn Negen as VP Commercial Strategy

Utrecht, The Netherlands, 15 June 2021 – AM-Pharma B.V., an…